Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease). Concurrent opportunistic infections (The experimental treatment bein g evaluated in this protocol depends on an intact immune sy stem. Patients who ha ve decreased immune- competence may be less responsive to the ex perimental treatment and more susceptible to its toxicities). Any vaccinations four weeks prior to the first vaccination cycle or live vaccines at any time during the study. SCREENING EVALUATIONS Note: Testing for screening evaluation is c onducted under the NCI-SB companion protocol, 99- C-0128 (Evaluation for NCI Surgery Bran ch Clinical Research Protocols). 2.2.1 Within 3 Months Prior to Part Two Registration x HIV antibody titer, HBsAg determination, and anti-HCV x Confirmation of diagnosis of metastatic melanoma, gastrointestinal, or genitourinary cancer by the NCI Laboratory of Pathology. (Note: Testing is pe rmitted to be conducted at any time prior to Part Two registration.) 2.2.2 Within 4 Weeks Prior to Part Two Registration x Complete history and physical examination. (Note: Patient history may be obtained within 8 weeks prior to Part Two registration.) x Imaging evaluation to determine baseline di sease status. This may include CT, MRI, PET, and/or photography. 2.2.3 Within 7 Days Prior to Part Two Registration x Screening blood tests: o CBC w/differential o Chemistries: Creatinine, ALT/GPT, AST/GOT, Total bilirubin o Lymphocyte phenotyping (TBNK) x Urinalysis, with culture if indicated Abbreviated Title: mRNA-Based, Cancer Vaccine Version Date: January 23, 2019 22x Physical examination, including ECOG of 0 or 1 (see Appendix B ) x Weight and vital signs x ȕ-HCG pregnancy test (serum or urine) on all women of child-bearing potential REGISTRATION AND TREATMENT ASSIGNMENT PROCEDURES 2.3.1 Prior to Registration for this Protocol Patients will initially sign the consent for a nd enroll on protocol 03-C-0277 prior to tumor harvest and leukapheresis for ge neration of the cell product. Patie nts will then sign the consent for and register for Part One of this trea tment protocol. If the mRNA vaccine meets the requirements specified in the Certificate of Analysis (CoA) ( Appendix C ) to include USP <71> sterility testing, the vaccine will be released by Moderna and shipped to the NIH Clinical Center Pharmacy, where it will be disp ensed and administered to the patient after receipt by the pharmacy of a physician’s order. The patient must meet the eligibility criteria and be registered to Part Two of this treatment protocol before receiving the vaccine. If the mRNA vaccine does not meet the requirements specified in the CoA, the vaccine will not be released by Moderna and the patient will be ta ken off-study (Section 3.8.2). 2.3.2 Registration Procedure Registration will be a two-part process. Authorized staff must register an eligible candidate with the NCI Central Registration Office (NCI-CRO) w ithin 24 hours of signing consent. To initially register a subject after the participant has signed the consent, complete the top portion of the registration Eligibility Checklist from the website (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm) indicating that the patient is being registered for Part One and send via encrypted email to the NCI-CRO at ncicentralregistration-l@mail.nih.gov. Once the mRNA vaccine meets the requirements specified in the CoA and the vaccine is released by Moderna, and eligibility is confirmed after completion of scr eening studies, authorized staff must complete the remainder of the eligibility checklist, indicating that the patient is being registered for Part Two (treatment on study). Email the completed registration Eligibility Checklist to the NCI-CRO at ncicentralregistration-l@mail.nih.gov. After confirmation of eligibility at the NCI-CRO, CRO staff will call pharmacy to advise them of the acceptance of the patient on the protocol prio r to the release of any investigational agents. Verification of registration will be forwarded electronically via email to the research team. A recorder is available during non-working hours. Subjects that do not meet scr eening criteria should be removed from the study following the procedure in Section 3.8.3.